Why Pfizer (PFE) Stock Is Up Today

NEW YORK (TheStreet) -- Pfizer  (PFE) rose slightly on Tuesday after the U.S. pharmaceutical giant withdrew its $118 billion bid to take over British rival AstraZeneca  (AZN) on Monday.

The 5 p.m. deadline to make a deal approached without indication that AstraZeneca would change its mind about a takeover, and Pfizer decided to walk away after a month-long, public back-and-forth with the British pharmaceutical company two hours before the deadline. British rules mandate a cool-down period between the two sides.

This was the third time Pfizer had sweetened the deal and increased the price, and many investors believed the $118 billion mark would facilitate a deal or at least force AstraZeneca to seriously consider the offer.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Goldman Sachs also reinstated coverage on Pfizer with a "buy" rating and set a $35 price target.

The stock was up 0.36% to $29.59 at 11 a.m.

Separately, TheStreet Ratings team rates PFIZER INC as a "buy" with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate PFIZER INC (PFE) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux